| 1.06 -0.01 (-0.93%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.7 |
| Resists | First : | 1.25 | Second : | 1.46 |
| Pivot price | 0.9 |
|||
| Supports | First : | 0.89 | Second : | 0.67 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 0.9 |
| MA(100) : | 1.62 |
MA(250) : | 1.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 65.6 |
D(3) : | 72.8 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 2.39 | Low : | 0.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMRN ] has closed below upper band by 19.4%. Bollinger Bands are 6.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.13 - 1.14 | 1.14 - 1.14 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Mon, 19 Jan 2026
Immuron Reports Continued Sales Growth - markets.businessinsider.com
Mon, 19 Jan 2026
Immuron’s Travelan diarrhea supplement lifts H1 sales to AUD$4.2M - Stock Titan
Mon, 15 Dec 2025
Immuron (IMRN) Struggles After Announcing Trial Results - Yahoo Finance
Sat, 13 Dec 2025
Immuron Limited Announces Quotation of New Securities on ASX - The Globe and Mail
Wed, 10 Dec 2025
Immuron Limited Issues New Shares to Bolster Financial Position - TipRanks
Wed, 03 Dec 2025
Immuron (NASDAQ: IMRN) adds U.S. DoD award as ETEC colostrum trial reports topline data next week - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 265 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 136 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.01 |
| Profit Margin | -71.6 % |
| Operating Margin | -85.6 % |
| Return on Assets (ttm) | -26.1 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 29.2 % |
| Gross Profit (p.s.) | 0.59 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.74 |
| PEG Ratio | 0 |
| Price to Book value | 53 |
| Price to Sales | 1.17 |
| Price to Cash Flow | -1.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|